The Burkholderia Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Burkholderia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Burkholderia Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Burkholderia Infections by 16 companies/universities/institutes. The top development phase for Burkholderia Infections is preclinical with ten drugs in that stage. The Burkholderia Infections pipeline has 11 drugs in development by companies and five by universities/ institutes. Some of the companies in the Burkholderia Infections pipeline products market are: Planet Biotechnology, Defence Science and Technology Laboratory and University of Texas at Austin OTC.
The key targets in the Burkholderia Infections pipeline products market include Beta Lactamase (EC 3.5.2.6), Elongation Factor G (EFG), and Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI (NADH Dependent Enoyl ACP Reductase or Enoyl ACP Reductase or EC 1.3.1.9).
The key mechanisms of action in the Burkholderia Infections pipeline product include Beta Lactamase (EC 3.5.2.6) Inhibitor with one drug in Preclinical. The Burkholderia Infections pipeline products include five routes of administration with the top ROA being Intravenous and seven key molecule types in the Burkholderia Infections pipeline products market including Small Molecule, and Vaccine.
Burkholderia Infections overview
Burkholderia is a genus of Pseudomonadota whose pathogenic members include the Burkholderia cepacia complex, which attacks humans and Burkholderia mallei, responsible for glanders, a disease that occurs mostly in horses and related animals; Burkholderia pseudomallei, causative agent of melioidosis; and Burkholderia cepacia, an important pathogen of pulmonary infections in people with cystic fibrosis (CF).
For a complete picture of Burkholderia Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
